Makers of some of the most lucrative pharmaceutical products ever produced are headed for a slump in revenues as deliveries of Covid-19 vaccines almost halve next year, according to new forecasts.
Airfinity, a health data analytics group, said Pfizer, BioNTech and Moderna had begun raising vaccine prices but this would not fully compensate for the drop in demand for Covid inoculations in 2023. It forecasts sales of Covid-19 vaccines falling by about a fifth to $47bn next year.
The average price per dose next year will rise to $37, which is double the amount charged for Covid jabs in 2021. But prices may be a lot higher in the US, which is moving from government purchases to a private market and where Moderna has said it could charge up to $100 per shot.